Skip to main content

Day: November 24, 2025

StoneX Group Inc. Reports Fiscal 2025 Fourth Quarter Financial Results

Record Fiscal Year Results, with Net Income of $305.9 million, up 17% Quarterly Net Operating Revenues of $585.1 million, up 29%   Record Quarterly Net Income of $85.7 million, Quarterly ROE of 15.2% Quarterly Diluted EPS of $1.57 per share, Fiscal Year of $5.89 per share NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — StoneX Group Inc. (the “Company”; NASDAQ: SNEX), a leading financial services franchise connecting clients to global markets, today announced its financial results for the fiscal fourth quarter and year ended September 30, 2025. Sean O’Connor, the Company’s Executive Vice-Chairman of the Board, stated, “We are pleased to announce our results to close out fiscal year 2025, one which marked another record annual performance in both revenues and net income and one in which we continue to grow both our product capabilities...

Continue reading

Woodward Reports Record Sales & Earnings for Fiscal Year 2025

Fiscal 2026 Guidance Reflects Robust Growth FORT COLLINS, Colo., Nov. 24, 2025 (GLOBE NEWSWIRE) — Woodward, Inc. (NASDAQ:WWD) today reported financial results for its fiscal year 2025 and fourth quarter ending September 30, 2025. All amounts are presented on an as reported (U.S. GAAP) basis unless otherwise indicated. All per share amounts are presented on a fully diluted basis. All comparisons are made to the same period of the prior year unless otherwise stated. All references to years are references to the Company’s fiscal year unless otherwise stated. Fourth Quarter and Fiscal Year 2025 Overview  Fourth Quarter 2025   Fiscal Year 2025Net sales $995M, +16%   $3.6B, +7%Net earnings $138M, +66%   $442M, +19%Adjusted net earnings1 $129M, +49%   $424M, +12%Earnings per share (EPS) $2.23, +64%   $7.19, +20%Adjusted...

Continue reading

iBio to Participate in the 8th Annual Evercore Healthcare Conference

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) — iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the 8th Annual Evercore Healthcare Conference, taking place December 2–4, 2025, in Miami. Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will participate in a fireside chat on Thursday, December 4, 2025, at 8:45 a.m. ET. Dr. Brenner will outline iBio’s ongoing efforts to move its next-generation obesity pipeline into clinical development, emphasizing the promising new non-human primate data for IBIO-610, a potential first-in-class Activin E antibody, presented at ObesityWeek® 2025. Felipe Duran, iBio’s Chief Financial Officer, will be available with Dr. Brenner for one-on-one meetings during the conference. A livestream...

Continue reading

AVITA Medical to Present at the Piper Sandler 37ᵗʰ Annual Healthcare Conference

VALENCIA, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025, at 8:30 a.m. EST. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference. A live audio webcast of the presentation will be accessible under the Events & Presentations section of AVITA Medical’s website at https://ir.avitamedical.com/events-and-presentations. A replay of the webcast will be available following the conclusion of the event. About AVITA Medical, Inc. AVITA Medical® is a leading therapeutic acute wound care company delivering transformative...

Continue reading

Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook

Financial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty (“HCRx”) of a non-dilutive royalty financing valued up to $71 million Progress in the JNJ-1900 (NBTXR3) global development program announced including first data from a Phase 1 esophageal cancer study sponsored by The University of Texas MD Anderson Cancer Center (“MD Anderson”) Completed the NANORAY-312 sponsorship transfer to Johnson & Johnson in the majority of regions Advanced the Curadigm Nanoprimer program with updated plans for internal pipeline development and external collaborations Clinical updates from ongoing or completed JNJ-1900 (NBTXR3) Phase 1 studies sponsored by Nanobiotix or MD Anderson in melanoma, lung cancer amenable to re-irradiation, pancreatic cancer, and esophageal cancer expected in 2026 €20.4...

Continue reading

First Financial Northwest, Inc. Announces Final Cash Liquidation Distribution

RENTON, Wash., Nov. 24, 2025 (GLOBE NEWSWIRE) — First Financial Northwest, Inc. (CUSIP 32022K102) (the “Company”) today announced that its Board of Directors has declared a final cash liquidation distribution in the amount of $1.30 per share pursuant to its previously announced Plan of Dissolution. The final cash liquidation distribution will be payable on December 12, 2025, to shareholders of record as of April 23, 2025, which was the record date set for the initial and all subsequent cash liquidation distributions. The Company previously declared an initial cash liquidation distribution of $22.00 per share payable on April 30, 2025. Including the final cash liquidation distribution to be paid on December 12, 2025, the Company will have paid a total of $23.30 per share, or approximately $215 million, in accordance with its Plan...

Continue reading

Exodus Enters Next Phase as a Crypto Payments Company With Agreement to Acquire W3C Corp, and its subsidiaries Baanx and Monavate

The company will acquire end-to-end payments infrastructure, positioning it to become an on-chain payments giant OMAHA, Neb., Nov. 24, 2025 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus” or the “Company”), a leading self-custodial cryptocurrency platform, today announced it has entered into a definitive agreement to acquire W3C Corp, the parent entity of Monavate Holdings Ltd. and its subsidiaries (collectively, “Monavate”) and Baanx.com Ltd. and Baanx US Corp (“Baanx”), two established providers of card and payments infrastructure serving fintech, crypto, and enterprise clients. The acquisition is subject to regulatory approvals. Upon the closing of the acquisition, Exodus plans to enter the arena of on-chain payments to become one of the few self-custodial wallets to control the end-to-end payments experience,...

Continue reading

Zoom Communications Reports Financial Results for the Third Quarter of Fiscal Year 2026

Third quarter total revenue of $1,229.8 million, up 4.4% year over year as reported and 4.2% in constant currency Third quarter Enterprise revenue of $741.4 million, up 6.1% year over year Third quarter GAAP operating margin of 25.2% and non-GAAP operating margin of 41.2% Third quarter operating cash flow of $629.3 million, up 30.2% year over year Third quarter operating cash flow margin of 51.2% and free cash flow margin of 50.0% Third quarter GAAP EPS of $2.01, up 204.5% year over year, and non-GAAP EPS of $1.52, up 10.1% year over year Number of customers contributing more than $100,000 in trailing 12 months revenue up 9.2% year over year Repurchased approximately 5.1 million shares of common stock in Q3, bringing the total shares repurchased under the current plan to 32.5 million Increased total common stock repurchase authorization...

Continue reading

Fluence Energy, Inc. Reports 2025 Financial Results and Initiates 2026 Guidance

ARLINGTON, Va., Nov. 24, 2025 (GLOBE NEWSWIRE) — Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its results for the three months and full fiscal year ended September 30, 2025.   Fiscal Year 2025 Financial HighlightsRevenue of $2.3 billion for fiscal year 2025 and $1.0 billion for the fourth quarter, compared to $2.7 billion and $1.2 billion from the same periods in fiscal 2024, respectively. GAAP gross profit margin improved to approximately 13.1% for fiscal year 2025 and approximately 13.7% for the fourth quarter, compared to 12.6% and 12.8% for the same periods in fiscal 2024, respectively.  Net loss of $68.0 million for fiscal year 2025 and net income of $24.1 million for...

Continue reading

PennantPark Floating Rate Capital Ltd. Announces Financial Results for the Fourth Quarter and Fiscal Year Ended September 30, 2025

MIAMI, Nov. 24, 2025 (GLOBE NEWSWIRE) — PennantPark Floating Rate Capital Ltd. (NYSE: PFLT) announced today its financial results for the fourth quarter and fiscal year ended September 30, 2025. HIGHLIGHTSQuarter ended September 30, 2025($ in millions, except per share amounts)Assets and Liabilities:  Investment portfolio(1) $ 2,773.3  Net assets $ 1,074.5  GAAP net asset value per share $ 10.83  Quarterly change in net asset value per share   (1.2 )%Credit Facility $ 683.8  2036 Asset-Backed Debt, net of unamortized deferred financing costs $ 284.6  2036-R Asset-Backed Debt, net of unamortized deferred financing costs $ 265.4  2037 Asset-Backed Debt, net of unamortized deferred financing costs $ 358.3  2026 Notes, net of unamortized deferred financing costs $ 184.6  Regulatory debt to equity   1.66x  Weighted...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.